Skip to main content
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
As of Mar 31
General1 sourcesNeutral

GC Cell Files Patent for CAR-NK Immunotherapy Targeting Solid Tumors

GC Cell has filed a patent for a CAR-NK immunotherapy targeting CLDN18.2, a protein expressed in gastric, pancreatic and esophageal cancers, expanding its solid tumor pipeline.

LJ
lee jeong-min
via 서울경제
ShareRead original

Read the full article at 서울경제 →

GC Cell Files Patent for CAR-NK Immunotherapy Targeting Solid Tumors

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

서울경제
서울경제
NewsData

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
Pharmac funds lifechanging cystic fibrosis medication for all ages - The National Tribune
Next
Audiology & Hearing Centers Expands Access to Oticon Zeal, the Next Generation of Discreet AI-Powered Hearing Technology

Related Articles

OmniVision Integrated Circuits Group, Inc. Announces Advance In Full Year IncomeGeneral
OmniVision Integrated Circuits Group, Inc. Announces Advance In Full Year Income
Unknown-3h ago-1 sources
TD SYNNEX Expects Q2 Results To ClimbGeneral
TD SYNNEX Expects Q2 Results To Climb
Unknown-3h ago-1 sources
Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares UpGeneral
Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up
Unknown-3h ago-1 sources